• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Varenicline reduces post-quit smoking relapses

bys25qthea
March 30, 2013
in Chronic Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

 

[tab]

Image: PD

1. Smokers randomized to varenicline plus counseling were more likely to abstain from smoking six months after quitting compared to those receiving placebo plus counseling. 

2. Patients randomized to varenicline reported fewer negative emotional effects compared to placebo group. 

Participants receiving varenicline plus counseling relapsed less frequently than those on placebo. In contrast to reports associating varenicline with an increased risk of neuropsychiatric events, patients randomized to varenicline reported fewer negative emotional effects. These results suggest varenicline may help smokers quit more successfully and have a better experience while doing so.

RELATED REPORTS

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

This study lacked the power (n=259) to detect a difference between varenicline and bupropion treatment groups. Verified outcome ascertainment of both abstinence (biochemical testing in addition to self-report) and emotional functioning (weekly assessments) are a strength. Follow-up investigation in a larger sample size with longer-term follow-up would provide insight intervention effectiveness.

Click to read the study in JAMA Psychiatry

[/tab]

[tab]

Image: PD

1. Smokers randomized to varenicline plus counseling were more likely to abstain from smoking six months after quitting compared to those receiving placebo plus counseling. 

2. Patients randomized to varenicline reported fewer negative emotional effects compared to placebo group. 

This [randomized controlled] trial assessed the effectiveness of varenicline and buproprion on smoking cessation and post-cessation symptoms in 294 volunteers. Participants were randomized by sex, ethnicity, history of depression, and baseline smoking rate into one of three groups: placebo plus in-person and phone call counseling (n=106), varenicline plus counseling (n=86), and bupropion plus counseling (n=102). Smoking abstinence was assessed at 10 weeks, 3 months, and 6 months post-quit; affective symptoms were recorded at weekly counseling sessions during the 12-week drug treatment phase.

At the 6-months post-quit, participants on varenicline were less likely to relapse (smoke for ≥7 days or smoke ≥1 cigarette for two consecutive weeks) than the placebo group (OR: 2.85, CI: 1.47-5.51) or bupropion group (OR: 1.73, CI: 0.93-3.21). Compared to placebo group participants, varenicline group participants reported lower depression and sadness levels, decreased smoking-related psychological reward, improved concentration, and reduced cravings.

In sum: Participants receiving varenicline plus counseling relapsed less frequently than those on placebo. In contrast to reports associating varenicline with an increased risk of neuropsychiatric events, patients randomized to varenicline reported fewer negative emotional effects. These results suggest varenicline may help smokers quit more successfully and have a better experience while doing so.

This study lacked the power (n=259) to detect a difference between varenicline and bupropion treatment groups. Verified outcome ascertainment of both abstinence (biochemical testing in addition to self-report) and emotional functioning (weekly assessments) are a strength. Follow-up investigation in a larger sample size with longer-term follow-up would provide insight intervention effectiveness.

Click to read the study in JAMA Psychiatry 

By Caroline Huang and Leah Hawkins

More from this author: Severe maternal childhood abuse associated with autism in offspring, 233 million women projected to lack modern contraceptives by 2015, Reminder intervention increases colorectal cancer screening rates, After-school program increases physical activity in overweight children, School-based therapy reduces asthma symptoms, Ethical argument for opt-out approach to DNR status in terminally ill children, Positive response to alcohol ads in young adolescence associated with alcohol-related problems later

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: varenicline
Previous Post

Children born late preterm birth at higher odds to fail standardized tests

Next Post

American Academy of Pediatrics updates its Medicaid Policy Statement

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 28, 2022
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 15, 2022
Secondhand smoke exposure counseling may be insufficient amongst cardiology inpatients
Chronic Disease

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

April 7, 2022
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Quick Take: Treatment for nicotine use disorder among Medicaid-enrolled adolescents and young adults

October 8, 2019
Next Post
American Academy of Pediatrics updates its Medicaid Policy Statement

American Academy of Pediatrics updates its Medicaid Policy Statement

Varicella vaccine provides 14-year protection against chicken pox

Varicella vaccine provides 14-year protection against chicken pox

Sexual activity rare in young adolescents, but often nonconsensual

Sexual activity rare in young adolescents, but often nonconsensual

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options